Becton Dickinson and Company (NYSE:BDX):
BD to Introduce Integrated Medication Management Platform Designed to Address Hospitals’ Greatest Challenges at #ASHP17.
The company is so far trading up since yesterday’s close of 219.1.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Company caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Business’s subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A..
Becton Dickinson and Company’s P/E ratio is 47.34 and the market value is 50.15B. As of the latest earnings report the EPS was $4.65 with 227.56M shares now outstanding.
Traders are feeling more bearish on the company recently if you take note of the increase in short interest. The firm realized a rise in short interest of 4.83% as of the latest report on October 31, 2017. Short interest increased 632,007 over that period. The days to cover decreased to 11.0 and the short interest percentage is 0.06% as of October 31.
Several investment analysts have released ratings on BDX recently. Equity analyst Morgan Stanley raised the price target on November 3 changing the price objective from $205.00 to $245.00 with a “Equal Weight” recommendation. Royal Bank Of Canada raised the price target of the stock on November 3 boosting the projection from $210.00 to $230.00 and issued a “Sector Perform” rating.
On November 3 Stifel Nicolaus maintained a stock rating of “Buy” with a current price target of $245.00. October 25 investment analysts at Royal Bank Of Canada left the stock rating at “Hold” projecting a price of $210.00.
October 24 investment analysts at Wells Fargo & Company maintained a company rating of “Positive” targeting a price of $235.00. On September 22, 2017 Wells Fargo & Company updated guidance on BDX giving it an initial rating of “Outperform”.